Recipharm sees H1 sales bump; Valeant pours $142M into plant; Aurobindo hits FDA issues;

> Swedish CDMO Recipharm said its sales were up 46% in H1 to about €185 million ($203 million). Report

> Valeant ($VRX) spent $142 million in the second quarter on restructuring work at a Bausch + Lomb plant in Waterford, Ireland. Release

> Aurobindo plant in India received an FDA Form 483. Report

> Federal officials have extracted a guilty plea and $450,000 in penalties from U.S.-based Aracoma Drug Company, a pharmacy that sold drugs over the Internet that had not been legally prescribed. Report

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.